.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Medtronic
Harvard Business School
Dow
US Army
Daiichi Sankyo
Colorcon
Citi
McKesson
Teva

Generated: November 18, 2017

DrugPatentWatch Database Preview

SELZENTRY Drug Profile

« Back to Dashboard

Which patents cover Selzentry, and what generic Selzentry alternatives are available?

Selzentry is a drug marketed by Viiv Hlthcare and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-one patent family members in fifty-nine countries and fifteen supplementary protection certificates in eleven countries.

The generic ingredient in SELZENTRY is maraviroc. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the maraviroc profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
SELZENTRY
maraviroc
SOLUTION;ORAL208984-001Nov 4, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
SOLUTION;ORAL208984-001Nov 4, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-003Nov 4, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-004Nov 4, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-003Nov 4, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-002Aug 6, 2007RXYesYes► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-004Nov 4, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-002Aug 6, 2007RXYesYes► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
SOLUTION;ORAL208984-001Nov 4, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-001Aug 6, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for SELZENTRY

Drugname Dosage Strength RLD Submissiondate
maravirocTablets150 mg and 300 mgSelzentry8/8/2011

Non-Orange Book Patents for Tradename: SELZENTRY

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives► Subscribe
7,217,714CCR5 modulators► Subscribe
7,041,667CCR5 modulators► Subscribe
6,586,431 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SELZENTRY

Country Document Number Estimated Expiration
Portugal1284974► Subscribe
Iceland5941► Subscribe
Norway330677► Subscribe
Brazil9916585► Subscribe
United Kingdom9922702► Subscribe
Algeria3464► Subscribe
Spain2215129► Subscribe
Canada2292984► Subscribe
Peru13712001► Subscribe
South Korea20010099931► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SELZENTRY

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
417Luxembourg► Subscribe91417, EXPIRES: 20220918
C008/2008Ireland► SubscribeSPC008/2008: 20081105, EXPIRES: 20220917
2008004Lithuania► SubscribePRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
C0007France► SubscribePRODUCT NAME: MARAVIROC; REGISTRATION NO/DATE: EU/1/07/418/001 20070918
1284974/01Switzerland► SubscribeFORMER OWNER: PFIZER INC., US
2008000011Germany► SubscribePRODUCT NAME: 4,4-DIFLUORO-N-((1S)-3-((1R,3S,5S)-3-(3-METHYL-5-(PROPAN-2-YL)-4H-1,2,4-TRIAZOL-4-YL)-8-AZABICYCLO(3.2.1)OCTAN-8-YL)-1-PHENYLPROPYL)CYCLOHEXANECARBOXAMIDE; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
4Finland► Subscribe
0338Netherlands► Subscribe
2008004,C1284974Lithuania► SubscribePRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
2008 00018Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
UBS
Cantor Fitzgerald
Cerilliant
US Department of Justice
Healthtrust
AstraZeneca
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot